NPPB and heart failure: In the Australia-New Zealand Heart Failure Group Trial in patients with chronic HF and reduced systolic function, levels of NT-proBNP above the median were associated with an increased risk for new decompensate HF events and all-cause mortality during the 18-month followup [19].